Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 186

Similar articles for PubMed (Select 21374066)

1.

Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.

Velosa J, Serejo F, Marinho R, Nunes J, Glória H.

Dig Dis Sci. 2011 Jun;56(6):1853-61. doi: 10.1007/s10620-011-1621-2. Epub 2011 Mar 5.

PMID:
21374066
2.

Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.

Hung CH, Lu SN, Wang JH, Hu TH, Chen CH, Huang CM, Lee CM.

Antivir Ther. 2011;16(7):959-68. doi: 10.3851/IMP1842.

PMID:
22024511
3.

Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.

Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P.

J Hepatol. 2010 May;52(5):652-7. doi: 10.1016/j.jhep.2009.12.028. Epub 2010 Mar 4.

PMID:
20346533
4.
5.

Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.

Hung CH, Lee CM, Lu SN, Wang JH, Hu TH, Tung HD, Chen CH, Chen WJ, Changchien CS.

J Viral Hepat. 2006 Jun;13(6):409-14.

PMID:
16842444
6.

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study.

Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL; Italian Association of the Study of the Liver Disease (AISF).

Hepatology. 2007 Mar;45(3):579-87.

PMID:
17326216
7.

Efficacy and anticarcinogenic activity of ribavirin combination therapy for hepatitis C virus-related compensated cirrhosis.

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

Intervirology. 2013;56(1):37-45. doi: 10.1159/000342746. Epub 2012 Oct 4.

PMID:
23037768
8.

Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.

Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, Macías J, Merino D, Márquez M, Ríos-Villegas MJ, Gea I, Merchante N, Rivero A, Torres-Cornejo A, Pineda JA; Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas.

Clin Infect Dis. 2013 Jun;56(11):1646-53. doi: 10.1093/cid/cit103. Epub 2013 Feb 19.

9.
10.

Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis.

Cheinquer N, Cheinquer H, Wolff FH, Coelho-Borges S.

Braz J Infect Dis. 2010 Sep-Oct;14(5):457-61.

11.

Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.

Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R; Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR).

Am J Gastroenterol. 2010 Oct;105(10):2164-72; quiz 2173. doi: 10.1038/ajg.2010.294. Epub 2010 Aug 10. Erratum in: Am J Gastroenterol. 2010 Oct;105(10):2308.

PMID:
20700116
12.

Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.

Huang CF, Yeh ML, Tsai PC, Hsieh MH, Yang HL, Hsieh MY, Yang JF, Lin ZY, Chen SC, Wang LY, Dai CY, Huang JF, Chuang WL, Yu ML.

J Hepatol. 2014 Jul;61(1):67-74. doi: 10.1016/j.jhep.2014.02.022. Epub 2014 Mar 5.

PMID:
24613362
13.

Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors.

Yamada G, Iino S, Okuno T, Omata M, Kiyosawa K, Kumada H, Hayashi N, Sakai T.

Clin Drug Investig. 2008;28(1):9-16. Erratum in: Clin Drug Investig. 2008;28(4):210.

PMID:
18081356
14.

Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response.

Pinzone MR, Zanghì AM, Rapisarda L, D'Agata V, Benanti F, Spartà D, Nunnari G, Cacopardo B.

Eur Rev Med Pharmacol Sci. 2014 Dec;18(2 Suppl):11-5.

15.

Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.

Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, Pol S, Trinchet JC.

World J Gastroenterol. 2007 Nov 14;13(42):5648-53.

16.
17.

Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis.

Azzaroli F, Accogli E, Nigro G, Trere D, Giovanelli S, Miracolo A, Lodato F, Montagnani M, Tamé M, Colecchia A, Mwangemi C, Festi D, Roda E, Derenzini M, Mazzella G.

World J Gastroenterol. 2004 Nov 1;10(21):3099-102.

18.

Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies.

Soriano V, Maida I, Núñez M, García-Samaniego J, Barreiro P, Martín-Carbonero L, González-Lahoz J.

Antivir Ther. 2004 Dec;9(6):987-92.

PMID:
15651757
19.

Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients.

Hsu CS, Huang CJ, Kao JH, Lin HH, Chao YC, Fan YC, Tsai PS.

PLoS One. 2013 Jul 23;8(7):e70458. doi: 10.1371/journal.pone.0070458. Print 2013.

20.

Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Hirakawa M, Ikeda K, Arase Y, Kawamura Y, Yatsuji H, Hosaka T, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Kumada H.

Intern Med. 2008;47(19):1637-43. Epub 2008 Oct 1.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk